Dipak is a Clinical Lecturer in Cardiovascular Medicine across the clinical sites attached to the University of Birmingham. He is also an Honorary Research Fellow at the Clinical Trials & Evaluation Unit, Royal Brompton Hospital / Imperial College, London and the Monash Centre of Cardiovascular Research & Education, Monash University, Melbourne.
Dipak is also Principal Investigator of the Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study (www.armcad.com)
His main interests are vascular function, coronary artery disease and heart failure. He regularly presents at major international conferences and is currently coordinating a global collaborative heart failure group. His teaching interests include clinical echocardiography and biomedical statistics.
Principal Investigator of the Alternative Risk Markers in Coronary Artery Disease (ARM-CAD) Study. Multi-centre research study to assess vascular dysfunction and angiographic coronary artery disease in high-risk populations. Secondary data analyses ongoing, including new concepts in arterial pressure compliance, pulse wave velocity measurements, 5-year follow-up data and assessment of biomarkers. (www.armcad.com)
Co-ordinator and steering committee member for the Beta Blockers in Heart Failure Collaborative Group (BB-meta-HF). Establishing a collaboration of global investigators involved in the major trials of beta-blockers in symptomatic left-ventricular dysfunction and undertaking a meta-analysis of individual patient data (n=18630). Currently in data-acquisition and analysis stage.
Principal Investigator of the Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Database. Cross-research database to incorporate current and future investigator-driven studies, improve data collection, standardise cardiovascular risk information and enhance recruitment into research projects. Commenced recruitment 2007 (currently n=4500).
Member of the authorship team for a Cochrane Review of erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Meta-analysis to assess the clinical benefits in terms of exercise tolerance, symptoms, quality of life and health outcomes. Initial Cochrane review publication Jan 2010.
Kotecha D*, Manzano L, Altman DG, Krum H, Erdem G, Williams N, Flather MD. Individual Patient Data Meta-Analysis of Beta-Blockers in Heart Failure: Rationale and Design. Syst Rev 2013;2:7.
Kotecha D*, New G, Collins P, Eccleston D, Krum H, Pepper J, Flather MD. Radial Artery Pulse Wave Analysis for Non-invasive Assessment of Coronary Artery Disease. Int J Cardiol 2012 (in-press). DOI: http://dx.doi.org/10.1016/j.ijcard.2012.03.098
Kotecha D*, New G, Flather M, Eccleston D, Pepper J, Krum H. Five-minute heart rate variability can predict obstructive angiographic coronary disease. Heart 2012;98:395-401.
Kotecha D*, Ngo K, Walters J, Manzano L, Palazzuoli A, Flather M. Erythropoietin as a treatment of anemia in heart failure: Systematic review of randomized trials. Am Heart J. 2011:161:822-831.
Kotecha D*, Flather M, McGrady M, Pepper J, New G, Krum H, Eccleston D. Contemporary predictors of coronary artery disease in patients referred for angiography. Eur J Cardiovasc Prev Rehabil. 2010:17: 280-288.
Ngo K*, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, Flather M. Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev. 2010:(1): CD007613.
Cohen-Solal A, Kotecha D*, van Veldhuisen D, Bohm M, Coats A, Roughton M, Babalis D, Poole-Wilson P, Tavazzi L, Flather M. Efficacy & safety of nebivolol in elderly heart failure patients with impaired renal function. Eur J Heart Fail. 2009;11(9):872-80.